We are monitoring the impact of COVID-19 on Schizophrenia Drugs Agents Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 8016
Share on
Share on

Global Schizophrenia Drugs Agents Market Size, Share, Trends & Growth Analysis Report – Segmented By Therapeutic Class, Treatment & Region – Industry Forecast (2020 to 2025)

Pulished: February, 2020
ID: 8016
Pages: 175

Schizophrenia Drugs Agents Market Size (2020 to 2025)

The size of the global schizophrenia drugs agents market was worth USD 6.96 billion in 2020 and is estimated to be growing at a CAGR of 2.4% to reach USD 7.84 billion by 2025. 

MARKET DRIVERS:

Growing awareness of psychiatric illnesses, expanded medical treatments for the treatment of major mental disorders, a large and robust pipeline, increasing acceptance of innovative schizophrenia therapeutics in emerging markets, and a rise in the number of schizophrenia patients have all resulted in the growth of the schizophrenia drugs agents market.

China and India are expected to offer growth possibilities for the global market to expand further. The major driving factors for market growth are favorable healthcare reforms, a large aging population, increased health awareness, and a low-cost base. According to the World Health Organization, schizophrenia affected nearly 50 million people worldwide in 2013. Even though the prevalence of schizophrenia is declining, the rate of care and prescription for this condition is rising, indicating that there are future growth opportunities in schizophrenia treatment. Compared to mergers and acquisitions, the partnership created by collaborations and partnerships has a positive and immediate effect on growth. Furthermore, manufacturers of schizophrenia medications are concentrating their efforts on identifying new revenue streams. To do this, manufacturers are focusing on emerging markets as future growth areas.

MARKET RESTRAINTS:

High investment costs and a lack of knowledge, on the other hand, are limiting the market growth. The achievement of medication adherence is a big obstacle for the global market for schizophrenia drug agents.

The lack of sample-based tests is a big challenge preventing healthcare companies from designing new treatments for the schizophrenia drug market. It's difficult for researchers to investigate the root causes of schizophrenia because doctors can't take brain tissue samples from patients as they can in a biopsy on a cancer tumor anywhere in the body. Drug side effects such as drowsiness, insomnia, Dry mouth, and various other disorders are restraining the global schizophrenia drug market's development.

Impact of COVID-19 on the global schizophrenia drugs agents market:

COVID-19 pandemic impacted every market as same as the schizophrenia market. The COVID-19 pandemic outbreak is affecting the mental health population due to exposure to substantial psychosocial stress. An increment in vigilance for psychosis symptoms in patients with COVID-19 is warranted. The schizophrenia drug market should retain the linear progression in growth.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2019 to 2025

Base Year

2019

Forecast Period

2020 to 2025

Segments Covered

By Therapeutic Class, Treatment and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global schizophrenia drugs agents market has been segmented and sub-segmented based on the therapeutic class, treatment, and region.

Schizophrenia Drugs Agents Market – By Therapeutic Class:

  • Second generation anti-psychotics
    • Risperdal
    • Invega
    • Zyprexa
    • Geodon
    • Seroquel
    • Latuda
    • Aristada
    • Fanapt
    • Saphris
    • Vraylar
  • Third generation anti-psychotics  
  • Others    

Based on therapeutic class, the second and third-generation anti-psychotics segments are the preferred treatment line for schizophrenia due to increased development in offering several advantages like improvement in treatment outcomes and decreased hospitalizations. The rise in the geriatric population and approvals for new products are the contributing factors in schizophrenia drugs.

Schizophrenia Drugs Agents Market – By Treatment:

  • Oral anti-psychotics       
  • Injectable anti-psychotics 

Based on treatment, the injectable antipsychotics segment is holding a significant share in the schizophrenia treatment market. Long-acting injectable antipsychotics offer better efficiency and tolerability due to the improvement of adherence and more stable pharmacokinetics. Injectable antipsychotics will reduce risks of relapse in schizophrenia outpatients in combination with the quality of psychosocial.

Schizophrenia Drugs Agents Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Regionally, the Global Schizophrenia Drugs Agents market was dominated by North America, closely followed by Europe. Asia Pacific is expected to grow at a high CAGR.

North American region dominates the share due to rising demand for schizophrenia treatment, the increment of medical cases, and growth in the geriatric population. Moreover, many of the population is affected by schizophrenia. So, developing awareness among people and launching new drugs via rigorous clinical trials are growth factors for the schizophrenia drug market.

The second-largest share in the schizophrenia drug market is the European region. It also owns some profitable drivers, such as an increase in cases of mental health problems and an increase in the geriatric population. Expenditure of healthcare can also boost market growth due to adapting fast treatment and the latest drugs. In countries like Singapore, Hong Kong, and Japan, there is a high prevalence of mental health problems that can fuel market growth. As expected, the least share is contributing by the MEA region due to undeveloped infrastructure and lack of facilities for mental health problems. At present, every region is developing by establishing numerous hospitals.

PROMISING COMPANIES IN THE MARKET:

Some of the notable companies leading the global schizophrenia drugs agents market profiled in this report are Johnson & Johnson, Sumitomo Dainippon, Eli Lilly, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Alkermes, Vanda Pharma, Allergan, and Pfizer.

KEY RECENT HAPPENINGS IN THIS MARKET:

  • In January 2018, to manufacture and sale of Rexulti tables, approval was received by Otsuka Pharmaceutical Co., Ltd.
  • In January 2018, FDA approval was received by Janssen Global Services for INVEGA SUSTENNA, once a month drug in schizophrenia drug. First and foremost, antipsychotic drugs have U.S. food and drug approval.
  • In 2019, U.S. lanced risperidone ISM for the treatment of patients with schizophrenia disorder.
  • In November 2017, for the usage of VRAYLAR, FDA approval was received by ALLERGAN for the treatment of schizophrenia. 

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapeutic class                     

                                5.1.1 Introduction           

                                5.1.2 Second generation anti-psychotics               

                                                5.1.2.1 Risperdal

                                                5.1.2.2 Invega

                                                5.1.2.3 Zyprexa

                                                5.1.2.4 Geodon

                                                5.1.2.5 Seroquel

                                                5.1.2.6 Latuda

                                                5.1.2.7 Aristada

                                                5.1.2.8 Fanapt

                                                5.1.2.9 Saphris

                                                5.1.2.10 Vraylar

                                5.1.3 Third generation anti-psychotics   

                                5.1.4 Others      

                                5.1.5  Y-o-Y Growth Analysis, By Therapeutic class            

                                5.1.6  Market Attractiveness Analysis, By Therapeutic class          

                                5.1.7  Market Share Analysis, By Therapeutic class           

                5.2 Treatment                  

                                5.2.1 Introduction           

                                5.2.2 Oral anti-psychotics             

                                5.2.3 Injectable anti-psychotics 

                                5.2.4 Y-o-Y Growth Analysis, By Treatment          

                                5.2.5 Market Attractiveness Analysis, By Treatment        

                                5.2.6 Market Share Analysis, By Treatment         

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Therapeutic class

                                                6.1.3.3 By Treatment

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Therapeutic class

                                                6.1.4.3 By Treatment

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 Therapeutic class

                                                6.1.5.3 By Treatment

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Johnson & Johnson                 

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Bristol-Myers Squibb                              

                8.3 AstraZeneca                               

                8.4 Sumitomo Dainippon                             

                8.5 Eli Lilly                           

                8.6 Alkermes                     

                8.7 Vanda Pharma                          

                8.8 Allergan                       

                8.9 Pfizer                            

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms of Therapeutic Class, By Treatment along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market                 
  1. Global Schizophrenia Drugs Market, By Region, From 2020 to 2025 (USD Billion)
  2. Global Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  3. Global Second generation anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  4. Global Third generation anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  5. Global Others Market, By Region, From 2020 to 2025 (USD Billion)
  6. Global Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  7. Global Oral anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  8. Global Injectable anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  9. North America Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  10. North America Second generation anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  11. North America Third generation anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  12. North America Others Market, By Region, From 2020 to 2025 (USD Billion)
  13. North America Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  14. North America Oral anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  15. North America Injectable anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  16. United States Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  17. United States Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  18. Canada Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  19. Canada Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  20. Europe Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  21. Europe Second generation anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  22. Europe Third generation anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  23. Europe Others Market, By Region, From 2020 to 2025 (USD Billion)
  24. Europe Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  25. Europe Oral anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  26. Europe Injectable anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  27. U.K. Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  28. U.K. Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  29. Germany Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  30. Germany Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  31. France Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  32. France Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  33. Italy Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  34. Italy Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  35. Spain Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  36. Spain Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  37. Asia Pacific Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  38. Asia Pacific Second generation anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  39. Asia Pacific Third generation anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  40. Asia Pacific Others Market, By Region, From 2020 to 2025 (USD Billion)
  41. Asia Pacific Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  42. Asia Pacific Oral anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  43. Asia Pacific Injectable anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  44. Japan Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  45. Japan Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  46. China Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  47. China Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  48. India Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  49. India Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  50. Australia Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  51. Australia Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  52. South Korea Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  53. South Korea Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  54. Latin America Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  55. Latin America Second generation anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  56. Latin America Third generation anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  57. Latin America Others Market, By Region, From 2020 to 2025 (USD Billion)
  58. Latin America Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  59. Latin America Oral anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  60. Latin America Injectable anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  61. Brazil Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  62. Brazil Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  63. Argentina Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  64. Argentina Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  65. Mexico Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  66. Mexico Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  67. Rest of Latin America Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  68. Rest of Latin America Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  69. Middle East and Africa Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  70. Middle East and Africa Second generation anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  71. Middle East and Africa Third generation anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  72. Middle East and Africa Others Market, By Region, From 2020 to 2025 (USD Billion)
  73. Middle East and Africa Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  74. Middle East and Africa Oral anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  75. Middle East and Africa Injectable anti-psychotics Market, By Region, From 2020 to 2025 (USD Billion)
  76. Middle East Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  77. Middle East Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)
  78. Africa Schizophrenia Drugs Market, By Therapeutic class, From 2020 to 2025 (USD Billion)
  79. Africa Schizophrenia Drugs Market, By Treatment, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample